Red Arrow Therapeutics Inc.

Red Arrow Therapeutics Inc. is a biotech startup founded in 2021 that specializes in an innovative nanopolymer drug-delivery system designed for the precise, programmable encapsulation and release of biologics. Based on research from the University of Tokyo, the company’s technology utilizes pH-sensitive polymeric micelles to stabilize therapeutic payloads, such as cytokines, allowing them to remain inactive during systemic circulation and release only upon reaching the acidic environment of a tumor. This mechanism aims to enhance on-target anti-tumor efficacy while significantly reducing the systemic toxicity often associated with potent biologics. The company is developing a pipeline of polymer-drug conjugates, with lead programs exploring the synergy of immune-modulating agents with existing cancer immunotherapies.

The company’s work addresses critical limitations in solid tumor treatments, where traditional immunotherapies often fail to infiltrate or effectively reach the tumor microenvironment without causing off-target damage. By enabling the precise delivery of proteins—ranging from small peptides to full-chain antibodies—the company seeks to expand the range of treatable cancers and improve outcomes for non-responders to current checkpoint inhibitors. Headquartered in Cambridge, Massachusetts, with additional operations in Tokyo, Japan, Red Arrow Therapeutics is backed by institutional investors including UTEC, Beyond Next Ventures, and others, and has secured support through prestigious accelerator programs and government research grants to advance its preclinical development and manufacturing capabilities.